CN1604787A - 通过低剂量施用组织因子途径抑制剂(tfpi)治疗脓毒病 - Google Patents

通过低剂量施用组织因子途径抑制剂(tfpi)治疗脓毒病 Download PDF

Info

Publication number
CN1604787A
CN1604787A CNA028250648A CN02825064A CN1604787A CN 1604787 A CN1604787 A CN 1604787A CN A028250648 A CNA028250648 A CN A028250648A CN 02825064 A CN02825064 A CN 02825064A CN 1604787 A CN1604787 A CN 1604787A
Authority
CN
China
Prior art keywords
tfpi
ala
analog
aglycosylated
hour
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028250648A
Other languages
English (en)
Chinese (zh)
Inventor
A·A·克里西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVARTIS VACCINES and DIAGNOSTIC Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of CN1604787A publication Critical patent/CN1604787A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Theoretical Computer Science (AREA)
  • Mathematical Physics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA028250648A 2001-10-15 2002-10-15 通过低剂量施用组织因子途径抑制剂(tfpi)治疗脓毒病 Pending CN1604787A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32880601P 2001-10-15 2001-10-15
US60/328,806 2001-10-15

Publications (1)

Publication Number Publication Date
CN1604787A true CN1604787A (zh) 2005-04-06

Family

ID=23282520

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028250648A Pending CN1604787A (zh) 2001-10-15 2002-10-15 通过低剂量施用组织因子途径抑制剂(tfpi)治疗脓毒病
CNA028249003A Pending CN1604790A (zh) 2001-10-15 2002-10-15 通过施用组织因子途径抑制剂(tfpi)治疗严重性肺炎

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA028249003A Pending CN1604790A (zh) 2001-10-15 2002-10-15 通过施用组织因子途径抑制剂(tfpi)治疗严重性肺炎

Country Status (17)

Country Link
US (2) US7674769B2 (enExample)
EP (2) EP1446140A4 (enExample)
JP (5) JP2005515214A (enExample)
KR (2) KR20050036867A (enExample)
CN (2) CN1604787A (enExample)
AU (2) AU2002365131B2 (enExample)
BR (2) BR0213293A (enExample)
CA (2) CA2463655A1 (enExample)
EA (2) EA200400549A1 (enExample)
HU (2) HUP0500472A2 (enExample)
IL (2) IL161408A0 (enExample)
IS (2) IS7223A (enExample)
MX (2) MXPA04003547A (enExample)
NO (2) NO20041997D0 (enExample)
PL (2) PL372138A1 (enExample)
WO (2) WO2003032904A2 (enExample)
ZA (2) ZA200403601B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050036867A (ko) 2001-10-15 2005-04-20 카이론 코포레이션 조직인자경로 억제제（ｔｆｐｉ）의 투여에 의한 중증폐렴의 치료
JP2008500942A (ja) * 2003-01-08 2008-01-17 カイロン コーポレイション 組織因子経路インヒビターまたは組織因子経路インヒビター改変体を含有する安定化凍結乾燥組成物
WO2005019265A1 (en) 2003-08-13 2005-03-03 Chiron Corporation Improved method of purifying tfpi and tfpi analogs
CA2560103A1 (en) * 2004-03-17 2005-11-24 Chiron Corporation Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
MX2007012619A (es) * 2005-04-15 2008-01-11 Novartis Vaccines & Diagnostic Tratamiento de neumonia severa adquirida en comunidad por administracion de inhibidor de ruta de factor de tejido.
US20090214506A1 (en) * 2005-05-06 2009-08-27 Novartis Ag Use of TFPI to Treat Severe Bacterial Infections
CN102961746B (zh) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 TNFα抑制剂治疗腐蚀性多关节炎的用途
CA2612646C (en) * 2005-06-24 2015-11-24 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
AU2006272653A1 (en) * 2005-07-22 2007-02-01 Novartis Ag TFPI fragments as anti-microbial agents
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
WO2009014633A1 (en) * 2007-07-20 2009-01-29 Trustees Of The University Of Pennsylvania Method of treating acute respiratory distress syndrome
WO2009129164A1 (en) * 2008-04-15 2009-10-22 Novartis Ag Pharmaceutical combinations of tfpi-fragments and an antibiotic
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
US20120148542A1 (en) 2010-12-10 2012-06-14 Lifeline Scientific, Inc. Machine perfusion with complement inhibitors
CA2841013C (en) 2011-07-18 2020-04-21 Morphosys Ag Use of c-fms antagonists
AU2012337838B2 (en) * 2011-11-15 2016-04-21 Asahi Kasei Pharma Corporation Medicament for therapeutic treatment and/or improvement of sepsis
US9856316B2 (en) 2013-04-12 2018-01-02 Morphosys Ag Antibodies targeting M-CSF
US11908581B2 (en) 2018-04-10 2024-02-20 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
US11504071B2 (en) 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
WO2020084853A1 (ja) 2018-10-22 2020-04-30 旭化成ファーマ株式会社 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
CN118715235A (zh) * 2022-01-30 2024-09-27 西湖大学 预防和/或治疗由分支2菌株引起的艰难梭菌感染的组合物和方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4603106A (en) 1982-02-22 1986-07-29 The Rockefeller University Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3219248A1 (de) 1982-05-21 1983-11-24 Solco Basel AG, Birsfelden Verfahren zur gewinnung zellatmungsfoerdernder wirkstoffe aus kaelberblut
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4620948A (en) 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4711845A (en) 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
EP0179861A1 (en) 1984-04-19 1986-05-07 Agracetus Methods and vectors for transformation of plant cells
US4572798A (en) 1984-12-06 1986-02-25 Cetus Corporation Method for promoting disulfide bond formation in recombinant proteins
US4847201A (en) 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5110730A (en) 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5223427A (en) 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US4929700A (en) 1987-04-16 1990-05-29 Cetus Corporation Production of purified, biologically active, bacterially produced recombinant human CSF-1
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
DK412389D0 (da) 1989-01-19 1989-01-19 Novo Nordisk As Fremgangsmaade til udvinding af oprenset epi protein fra en fermenteringsoploesning
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
DK148890D0 (da) 1990-06-19 1990-06-19 Novo Nordisk As Farmaceutisk praeparat
DK0473564T3 (da) 1990-08-27 1996-04-15 Monsanto Co Antikoagulant kombination af LACI og sulfatiserede polysaccharider
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5212091A (en) * 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
US5276015A (en) 1992-03-18 1994-01-04 Washington University Method of inhibiting microvascular thrombosis
USRE36476E (en) 1992-03-18 1999-12-28 Washington University Method of inhibiting microvascular thrombosis
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
ES2139658T3 (es) * 1992-06-01 2000-02-16 Chiron Corp Utilizacion del inhibidor de coagulacion asociado a lipoproteinas (laci) para la preparacion de un medicamento para el tratamiento de inflamacion aguda o cronica.
KR950701820A (ko) 1992-06-11 1995-05-17 로저 에이. 윌리암스 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)
US5589359A (en) 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
JP3571378B2 (ja) * 1994-09-30 2004-09-29 扶桑薬品工業株式会社 感染症診断用プローブ
JP3761914B2 (ja) * 1994-11-17 2006-03-29 財団法人化学及血清療法研究所 アンチトロンビンｉｉｉ及び組織因子凝固系インヒビター含有血栓症治療剤
US5914316A (en) 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
US5612363A (en) 1995-06-02 1997-03-18 Berlex Laboratories, Inc. N,N-di(aryl) cyclic urea derivatives as anti-coagulants
EP0837883B1 (en) 1995-06-07 2005-08-10 Chiron Corporation Method of solubilizing, purifying, and refolding protein
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
US5885781A (en) 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
US5888968A (en) 1995-06-07 1999-03-30 Chiron Corporation TFPI formulation
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
AU706582B2 (en) 1996-03-25 1999-06-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Angiogenic inhibitor containing tissue factor pathway inhibitor
US5977057A (en) * 1996-05-08 1999-11-02 The University Of Vermont And State Agricultural College Thrombosis prophylaxis for factor VLEIDEN carriers
AU6042298A (en) * 1997-01-31 1998-08-25 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US5981471A (en) 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
ZA983497B (en) 1997-04-28 1999-10-25 Lilly Co Eli Activated protein c formulations.
IL121191A0 (en) 1997-06-29 1997-11-20 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6824997B1 (en) * 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
EP1124573A1 (en) 1998-10-22 2001-08-22 Eli Lilly And Company Methods for treating sepsis
DE69906568T2 (de) 1998-11-20 2004-02-12 Eli Lilly And Co., Indianapolis Behandlung von hämorrhagischem virusfieber mit protein c
AU4683299A (en) * 1999-06-11 2001-01-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Detection of streptococcus pneumoniae and immunization against streptococcus pneumoniae infection
WO2000077246A2 (en) 1999-06-14 2000-12-21 Novo Nordisk A/S A METHOD FOR IDENTIFYING A DRUG CANDIDATE HAVING AN INHIBITORY ACTION ON FVII-TF ACTIVITY, AND FVIIa/TF ACTIVITY INHIBITING COMPOUNDS
US6294648B1 (en) 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
DE60031999T2 (de) 1999-10-04 2007-06-06 Novartis Vaccines and Diagnostics, Inc., Emeryville Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
AU2908501A (en) 2000-01-06 2001-07-16 Eli Lilly And Company Combination therapy for the treatment of inflammatory and respiratory diseases
JP2003521938A (ja) 2000-02-11 2003-07-22 イーライ・リリー・アンド・カンパニー プロテインｃ誘導体
KR20020081330A (ko) 2000-02-16 2002-10-26 노오쓰웨스턴 유니버시티 폴리펩토이드 폐 계면활성제
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1370570B1 (en) 2001-02-28 2007-01-24 John H. Griffin Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
WO2002099098A1 (en) 2001-04-04 2002-12-12 American Diagnostica, Inc Method of preparation of stabilized thrombin-activatable fibrinolysis inhibitor (tafi) and methods of use thereof
DE10132307A1 (de) 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
KR20050036867A (ko) * 2001-10-15 2005-04-20 카이론 코포레이션 조직인자경로 억제제（ｔｆｐｉ）의 투여에 의한 중증폐렴의 치료
US20020198138A1 (en) 2002-06-07 2002-12-26 Macias William Louis Combination therapy for the treatment of inflammatory and respiratory diseases

Also Published As

Publication number Publication date
WO2003055442A2 (en) 2003-07-10
WO2003032904A3 (en) 2004-03-04
BR0213293A (pt) 2004-12-21
US20030139340A1 (en) 2003-07-24
NO20041997D0 (no) 2004-05-14
IS7224A (is) 2004-04-15
ZA200403601B (en) 2006-06-28
MXPA04003547A (es) 2004-07-22
JP2006008704A (ja) 2006-01-12
AU2002365131B2 (en) 2007-03-01
JP2010006839A (ja) 2010-01-14
IL161407A0 (en) 2004-09-27
NO20041996D0 (no) 2004-05-14
US7674769B2 (en) 2010-03-09
CA2463738A1 (en) 2003-07-10
AU2002340183B2 (en) 2008-11-13
WO2003032904A2 (en) 2003-04-24
PL374506A1 (en) 2005-10-31
ZA200403690B (en) 2005-03-08
JP2005515214A (ja) 2005-05-26
JP2006008706A (ja) 2006-01-12
EP1446140A4 (en) 2007-03-07
MXPA04003548A (es) 2004-07-22
IL161408A0 (en) 2004-09-27
HUP0501111A2 (en) 2007-12-28
HUP0500472A2 (hu) 2005-08-29
EP1446138A2 (en) 2004-08-18
EP1446138A4 (en) 2007-03-14
EA200400548A1 (ru) 2005-06-30
CN1604790A (zh) 2005-04-06
US20030139339A1 (en) 2003-07-24
JP2005506345A (ja) 2005-03-03
KR20050036867A (ko) 2005-04-20
WO2003055442A3 (en) 2004-03-04
AU2002365131A1 (en) 2003-07-15
PL372138A1 (en) 2005-07-11
CA2463655A1 (en) 2003-04-24
IS7223A (is) 2004-04-15
EP1446140A2 (en) 2004-08-18
EA200400549A1 (ru) 2005-02-24
BR0213292A (pt) 2006-05-23
KR20040040489A (ko) 2004-05-12

Similar Documents

Publication Publication Date Title
CN1604787A (zh) 通过低剂量施用组织因子途径抑制剂(tfpi)治疗脓毒病
US6063764A (en) Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU2002340183A1 (en) Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI)
JP2008540460A (ja) 重症細菌感染を処置するためのｔｆｐｉの使用
CN1522151A (zh) 经修饰的fvii用于治疗ards
JP2004210801A (ja) 敗血症を治療するためにリポタンパク質関連凝集インヒビターを用いる方法
US7662774B2 (en) Method for using lipoprotein associated coagulation inhibitor to treat sepsis
AU2007202500A1 (en) Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
US20080286279A1 (en) Treatment of Severe Community-Acquired Pneumonia by Administration of Tissue Factor Pathway Inhibitor (Tfpi)
JP2008536859A (ja) 組織因子経路阻害剤（ｔｆｐｉ）の投与による重度の市中肺炎の処置
CN1929858A (zh) 因子Ⅶa治疗创伤的晚期并发症的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: NOVARTIS VACCINES & DIAGNOSTIC

Free format text: FORMER OWNER: CHIRON CORP.

Effective date: 20080530

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20080530

Address after: Delaware

Applicant after: Novartis Vaccines & Diagnostic Inc.

Address before: American California

Applicant before: Chiron Corporation

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050406